AI Terminal
UCB
Transaction in Own Shares • Mar 21, 2025
4017_pos_2025-03-21_3afbbba4-f051-4fd8-9b90-c773034f99b0.pdf
Transaction in Own Shares
Open in ViewerOpens in native device viewer
Acquisition of own shares
Brussels (Belgium), 21 March 2025 – 20:00 (CET) – Regulated information
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ("UCB" or the "Company) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2025.
Under this program, UCB has requested a financial intermediary to repurchase up to 700,000 UCB shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 30 June 2025, effective as from 10 March 2025, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2025, UCB repurchased 152,859 UCB shares on Euronext Brussels in the period from 14 March 2025 up to and including 20 March 2025, as follows:
| Date of repurchase |
Number of shares |
Average Price Paid |
Total | Lowest Price Paid |
Highest Price Paid |
|---|---|---|---|---|---|
| 14 March 2025 | 28.559 | 179,72 € | 5.132.486,40 € | 178,00 € | 181,20 € |
| 17 March 2025 | 25.000 | 184,29 € | 4.607.277,50 € | 179,75 € | 184,95 € |
| 18 March 2025 | 32.000 | 182,34 € | 5.834.800,00 € | 180,60 € | 185,45 € |
| 19 March 2025 | 32.300 | 181,01 € | 5.846.771,58 € | 180,00 € | 182,30 € |
| 20 March 2025 | 35.000 | 179,52 € | 6.283.081,00 € | 177,90 € | 180,85 € |
This press release is available on UCB SA/NV's website via the following link.
For further information, contact UCB:
Investor Relations Antje Witte T +32 2 559 94 14 [email protected]
Sahar Yazdian T: +32.2.559.9137 [email protected]
Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
